The The Drug Cell consortium, led by the French Blood Establishment (EFS), GPI, MGA Technologies, and the AFM-Téléthon Stem Cell Research Center, has secured a record-breaking €152 million funding from the European Union.
The goal: to build a modular and scalable cell therapy manufacturing plant in France by 2031.
Bringing together academic and industrial leaders, including Carroucell and EVerZom, this initiative aims to establish a sovereign European production capability, a field still largely dominated by the U.S. and Asia.
As Hervé de Malliard, CEO of MGA Technologies, states: “Our goal is to democratize access to these costly treatments by automating processes and making production viable in Europe.”
A significant leap forward for innovation and European health independence!
In the Same Category
Chronicles of a small industrialist who dreams of re-enchanting France – Episode 52
In 2050, French industry has rediscovered its genius. Rooted in history, driven by innovation. AI, energy and biology work together, not against each other. Factories are human-centric, sustainable and intelligent. Maison MGA stands at the crossroads of science,...
They are talking about us – Maison MGA and acquisition of Myriade
La Maison MGA has recently been featured in several regional and specialized media outlets, which have reported on our industrial and strategic news. In Lyon Éco et Culture, the acquisition of Myriade is presented as an important step in strengthening our expertise in...